BR9909859A - Sequências de oligonucleotìdeos anti-sentido do fator de crescimento semelhante à insulina ii e métodos de uso das mesmas para modular o crescimento celular - Google Patents

Sequências de oligonucleotìdeos anti-sentido do fator de crescimento semelhante à insulina ii e métodos de uso das mesmas para modular o crescimento celular

Info

Publication number
BR9909859A
BR9909859A BR9909859-8A BR9909859A BR9909859A BR 9909859 A BR9909859 A BR 9909859A BR 9909859 A BR9909859 A BR 9909859A BR 9909859 A BR9909859 A BR 9909859A
Authority
BR
Brazil
Prior art keywords
methods
insulin
sequences
growth
modulate cell
Prior art date
Application number
BR9909859-8A
Other languages
English (en)
Inventor
Jim A Wright
Aiping H Young
Yoon S Lee
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Publication of BR9909859A publication Critical patent/BR9909859A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>"SEQuêNCIAS DE OLIGONUCLEOTìDEOS ANTISENTIDO DO FATOR DE CRESCIMENTO SEMELHANTE à INSULINA II E MéTODOS DE USO DAS MESMAS PARA MODULAR O CRESCIMENTO CELULAR". Esta invenção se refere a oligonucleotídeos complementares aos genes IGF-II, os quais modulam o crescimento celular nos mamíferos. Esta invenção também se refere a métodos para usar tais compostos na inibição do crescimento de células tumorais nos mamíferos. Esta invenção também se refere a composições farmacêuticas compreendendo um excipiente farmaceuticamente aceitável e uma quantidade eficaz de um composto desta invenção.
BR9909859-8A 1998-04-23 1999-04-23 Sequências de oligonucleotìdeos anti-sentido do fator de crescimento semelhante à insulina ii e métodos de uso das mesmas para modular o crescimento celular BR9909859A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8279198P 1998-04-23 1998-04-23
PCT/CA1999/000323 WO1999055854A2 (en) 1998-04-23 1999-04-23 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth

Publications (1)

Publication Number Publication Date
BR9909859A true BR9909859A (pt) 2000-12-19

Family

ID=22173486

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9909859-8A BR9909859A (pt) 1998-04-23 1999-04-23 Sequências de oligonucleotìdeos anti-sentido do fator de crescimento semelhante à insulina ii e métodos de uso das mesmas para modular o crescimento celular
BR9909809-1A BR9909809A (pt) 1998-04-23 1999-04-23 Sequências de oligonucleotìdeo anti-sentido de neuropilina e métodos de usar as mesmas para modular o desenvolvimento de célula

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9909809-1A BR9909809A (pt) 1998-04-23 1999-04-23 Sequências de oligonucleotìdeo anti-sentido de neuropilina e métodos de usar as mesmas para modular o desenvolvimento de célula

Country Status (11)

Country Link
US (2) US6417169B1 (pt)
EP (2) EP1073728A2 (pt)
JP (2) JP2002512792A (pt)
KR (2) KR20010042849A (pt)
CN (2) CN1298444A (pt)
AU (2) AU747639C (pt)
BR (2) BR9909859A (pt)
CA (2) CA2326824A1 (pt)
IL (2) IL138976A0 (pt)
NZ (2) NZ508354A (pt)
WO (2) WO1999055855A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
KR100441201B1 (ko) * 2001-09-10 2004-07-23 대한민국 리포터 유전자를 포함하는 티벡터용 플라스미드 및 그 제조방법
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
MXPA05012620A (es) 2003-05-21 2006-05-25 Bios Chile I G S A Marcadores para celulas precancerosas y cancerosas y metodo para interferir con la proliferacion celular.
WO2005049648A2 (en) * 2003-07-09 2005-06-02 The University Of Iowa Research Foundation Chimeric or fusion constructs of insulin-like growth factor binding proteins as chemotherapeutic agents
EP1661582A1 (en) * 2003-08-21 2006-05-31 Kyowa Hakko Kogyo Co., Ltd. Cancer metastasis inhibitor
US20060193772A1 (en) * 2003-09-24 2006-08-31 Atsushi Ochiai Drugs for treating cancer
KR100818332B1 (ko) * 2006-03-21 2008-04-02 퓨리메드 주식회사 녹용으로부터 분리된 신규 인슐린 유사 성장 인자 2의 폴리펩타이드 및 이의 유전자
MX2009012421A (es) * 2007-05-17 2009-12-01 Genentech Inc Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2.
KR20120003187A (ko) * 2010-07-02 2012-01-10 한국생명공학연구원 Ｎｅｕｒｏｐｉｌｉｎ １ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법
EP2522341A1 (en) 2011-05-13 2012-11-14 Tragex Pharma Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers
AU2014265142A1 (en) * 2013-05-17 2015-12-24 Medimmune, Llc Receptors for B7-H4
EP2823816A1 (en) 2013-07-09 2015-01-14 Tragex Pharma Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5766855A (en) 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
WO1993024655A1 (en) * 1992-05-27 1993-12-09 Amersham International Plc Rna analysis
JPH08506087A (ja) 1992-10-21 1996-07-02 テンプル ユニバーシティ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU1810499A (en) * 1997-12-09 1999-06-28 Children's Medical Center Corporation Antagonists of neuropilin receptor functional and use thereof

Also Published As

Publication number Publication date
KR20010042848A (ko) 2001-05-25
CN1298444A (zh) 2001-06-06
AU747639C (en) 2005-01-13
BR9909809A (pt) 2000-12-19
US6417169B1 (en) 2002-07-09
WO1999055855A3 (en) 2000-01-06
CA2326825A1 (en) 1999-11-04
WO1999055855A2 (en) 1999-11-04
NZ508354A (en) 2005-01-28
JP2002512793A (ja) 2002-05-08
KR20010042849A (ko) 2001-05-25
CN1298445A (zh) 2001-06-06
CA2326824A1 (en) 1999-11-04
NZ508353A (en) 2005-01-28
AU749802B2 (en) 2002-07-04
WO1999055854A2 (en) 1999-11-04
AU3402199A (en) 1999-11-16
IL138977A0 (en) 2001-11-25
IL138976A0 (en) 2001-11-25
AU747639B2 (en) 2002-05-16
WO1999055854A3 (en) 2000-06-29
JP2002512792A (ja) 2002-05-08
AU3402299A (en) 1999-11-16
EP1073729A2 (en) 2001-02-07
EP1073728A2 (en) 2001-02-07
US20020187954A1 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
BR9909859A (pt) Sequências de oligonucleotìdeos anti-sentido do fator de crescimento semelhante à insulina ii e métodos de uso das mesmas para modular o crescimento celular
van Beuningen et al. Differential effects of local application of BMP-2 or TGF-β1 on both articular cartilage composition and osteophyte formation
Mi et al. Adenovirus‐mediated gene transfer of insulin‐like growth factor 1 stimulates proteoglycan synthesis in rabbit joints
BR9804437A (pt) Compostos para a osteoporose
KR101340458B1 (ko) 하이드로겔을 포함하는 연골 이식용 조성물
CY1110941T1 (el) Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας
BR9811022A (pt) Composto, composição farmacêutica, e, processo para preparação de um composto
BR9607383A (pt) Composição farmacêutica útil para a transfecção de um ácido nucléico e utilização desta composição
CA2374003A1 (en) Improved cellular uptake of bioactive agents
GC0000178A (en) Protease inhibitors
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
ID21897A (id) Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
DE50111152D1 (de) Polyurethan und dessen verwendung zur modifizierung rheologischer eingenschaften
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
AR022423A1 (es) Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
HUP0002683A2 (hu) Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek
BR0008416A (pt) Composto, formulação e composição farmacêuticas, métodos para inibir o fluxo de potássio de uma célula, para o tratamento ou prevenção de um evento de doença falciforme, e, para melhorar a resistência à degradação em um meio biológico de um inibidor de canal de potássio compreendendo uma porção fenila
BR9909739A (pt) Benzotiadiazóis e derivados
JP2002503714A5 (pt)
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
CA2338415A1 (en) Preparation of thioarabinofuranosyl compounds and use thereof
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
CA2321149A1 (en) Antitumor agents
BR9907990A (pt) Sequência de oligonucleotideos complementares aos genes tiorredoxina ou tiorredoxina reductase e métodos de utilização dos mesmos para modular o crescimento de células

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.